BioMerieux Invests $15M in Quanterix as Part of Test Development Partnership | GenomeWeb

NEW YORK (GenomeWeb News) – BioMérieux and Quanterix announced today a deal granting BioMérieux worldwide exclusive rights to Quanterix's Single Molecule Array (SiMoA) technology in clinical laboratories and for industrial applications.

BioMérieux also took an initial $15 million stake in the Lexington, Mass.-based diagnostics firm as part of an $18.5 million Series C financing round announced by Quanterix today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.